NASDAQ:GNPXGenprex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genprex Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.78 +0.01 (+0.36 %) (As of 05/29/2020 12:16 PM ET) Add Compare Share Today's Range$2.68Now: $2.78▼$2.8250-Day Range$1.99MA: $2.63▼$3.5452-Week Range$0.23Now: $2.78▼$7.03Volume7,830 shsAverage Volume4.32 million shsMarket Capitalization$91.32 millionP/E RatioN/ADividend YieldN/ABeta-1.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGenprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Genprex has a potential upside of 79.9% from its current price of $2.78.Amount of Analyst CoverageGenprex has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesGenprex has received 193 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenprex has received 211 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenprex has received 52.23% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote “Outperform” if you believe GNPX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 29.01% of the stock of Genprex is held by insiders.Percentage Held by InstitutionsOnly 2.58% of the stock of Genprex is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioGenprex has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNPX Previous Symbol CUSIPN/A CIK1595248 Webwww.genprex.com Phone512-370-4081Debt Debt-to-Equity RatioN/A Current Ratio34.48 Quick Ratio33.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book3.81Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,650,000.00 Net MarginsN/A Return on Equity-157.02% Return on Assets-146.08%Miscellaneous EmployeesN/A Outstanding Shares32,850,000Market Cap$91.32 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:GNPX Rates by TradingView Receive GNPX News and Ratings via Email Sign-up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Genprex (NASDAQ:GNPX) Frequently Asked Questions How has Genprex's stock been impacted by COVID-19 (Coronavirus)? Genprex's stock was trading at $2.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNPX shares have increased by 14.9% and is now trading at $2.78. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Genprex? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genprex. When is Genprex's next earnings date? Genprex is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Genprex. How were Genprex's earnings last quarter? Genprex Inc (NASDAQ:GNPX) announced its earnings results on Monday, April, 1st. The company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.10. View Genprex's earnings history. What price target have analysts set for GNPX? 2 Wall Street analysts have issued twelve-month price objectives for Genprex's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Genprex's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price. View analysts' price targets for Genprex. Has Genprex been receiving favorable news coverage? Media stories about GNPX stock have trended somewhat negative on Friday, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Genprex earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutGenprex. Who are some of Genprex's key competitors? Some companies that are related to Genprex include Kamada (KMDA), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), Menlo Therapeutics (MNLO), Geron (GERN), OrganiGram (OGI), TherapeuticsMD (TXMD), Selecta Biosciences (SELB), MannKind (MNKD), Ovid Therapeutics (OVID), Avid Bioservices (CDMO), Lannett (LCI), Osmotica Pharmaceuticals (OSMT), Avadel Pharmaceuticals (AVDL) and Concert Pharmaceuticals (CNCE). View all competitors. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), Ibio (IBIO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), FuelCell Energy (FCEL) and vTv Therapeutics (VTVT). Who are Genprex's key executives? Genprex's management team includes the following people: Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)Mr. Ryan M. Confer, Chief Financial Officer (Age 37)Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board What is Genprex's stock symbol? Genprex trades on the NASDAQ under the ticker symbol "GNPX." Who are Genprex's major shareholders? Genprex's stock is owned by many different retail and institutional investors. Top institutional investors include Advisor Group Holdings Inc. (0.20%), IHT Wealth Management LLC (0.13%), Bank of New York Mellon Corp (0.08%), Frontier Wealth Management LLC (0.05%), Mid Atlantic Financial Management Inc. ADV (0.05%) and Jane Street Group LLC (0.03%). Company insiders that own Genprex stock include John Rodney Varner and Julien L Pham. View institutional ownership trends for Genprex. Which institutional investors are buying Genprex stock? GNPX stock was acquired by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., IHT Wealth Management LLC, Bank of New York Mellon Corp, Frontier Wealth Management LLC, Mid Atlantic Financial Management Inc. ADV, and Jane Street Group LLC. Company insiders that have bought Genprex stock in the last two years include John Rodney Varner, and Julien L Pham. View insider buying and selling activity for Genprex. How do I buy shares of Genprex? Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Genprex's stock price today? One share of GNPX stock can currently be purchased for approximately $2.78. How big of a company is Genprex? Genprex has a market capitalization of $91.32 million. What is Genprex's official website? The official website for Genprex is www.genprex.com. How can I contact Genprex? Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
